相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice
Kisoo Pahk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools
Alessandro Marturano et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)
A novel role of MMP2 in regulating platelet NOX2 activation
Cristina Nocella et al.
FREE RADICAL BIOLOGY AND MEDICINE (2020)
A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation
Kisoo Pahk et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
The non-haemostatic role of platelets in systemic lupus erythematosus
Petrus Linge et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis
Aaron Lerner et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2018)
Sub-Cellular Localization of Metalloproteinases in Megakaryocytes
Alessandro Malara et al.
CELLS (2018)
Early Abrogation of Gelatinase Activity Extends the Time Window for tPA Thrombolysis after Embolic Focal Cerebral Ischemia in Mice
Shanyan Chen et al.
ENEURO (2018)
MMP-13 binds to platelet receptors alpha IIb beta 3 and GPVI and impairs aggregation and thrombus formation
Joanna-Marie Howes et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2018)
A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling
Manuela Sebastiano et al.
BLOOD (2017)
Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation
Robert H. Scannevin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Matrix Metalloproteinases and Platelet Function
Paolo Gresele et al.
MATRIX METALLOPROTEINSES AND TISSUE REMODELING IN HEALTH AND DISEASE: CARDIOVASCULAR REMODELING (2017)
Matrix metalloproteinase collagenolysis in health and disease
Sabrina Amar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
Matrix metalloproteinase12 facilitated platelet activation by shedding carcinoembryonic antigen related cell adhesion molecule1
Jing Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions
Giuseppe Guglielmini et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity
Tom G. Mastenbroek et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm
A. Phillip Owens et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Modified platelet deposition on matrix metalloproteinase 13 digested collagen I
J. -M. Howes et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Captopril and Lisinopril Only Inhibit Matrix Metalloproteinase-2 (MMP-2) Activity at Millimolar Concentrations
Luciana B. Kuntze et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
Streptococcus sanguinis-induced cytokine and matrix metalloproteinase-1 release from platelets
Fabrice Cognasse et al.
BMC IMMUNOLOGY (2014)
Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial
Giampaolo Cerisano et al.
EUROPEAN HEART JOURNAL (2014)
β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy
Elen Rizzi et al.
FREE RADICAL BIOLOGY AND MEDICINE (2014)
Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma
G. J. Pennings et al.
PLATELETS (2014)
Intracellular matrix metalloproteinase-2 (MMP-2) regulates human platelet activation via hydrolysis of talin
Gerald Soslau et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation Correlation with ischaemic events
Massimo Lenti et al.
THROMBOSIS AND HAEMOSTASIS (2014)
C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture
Giovanni Cimmino et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Matrix Metalloproteinase Mmp-1a Is Dispensable for Normal Growth and Fertility in Mice and Promotes Lung Cancer Progression by Modulating Inflammatory Responses
Miriam Fanjul-Fernandez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis
M. Rahman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Platelets govern pre-metastatic tumor communication to bone
B. A. Kerr et al.
ONCOGENE (2013)
Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients
Ihosvany Fernandez Bello et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake
Silvia Giannini et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
A Selective Matrix Metalloproteinase-12 Inhibitor Retards Atherosclerotic Plaque Development in Apolipoprotein E-Knockout Mice
Jason L. Johnson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events
Luca Cecchetti et al.
BLOOD (2011)
Response MMP-9 in platelets: maybe, maybe not
Emanuela Falcinelli et al.
BLOOD (2011)
Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation
Paolo Gresele et al.
EUROPEAN HEART JOURNAL (2011)
Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol
Giovanni Cimmino et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall
C. Schulz et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Release of matrix metalloproteinases-1 and-2, but not-9, from activated platelets measured by enzyme-linked immunosorbent assay
Hanna Kalvegren et al.
PLATELETS (2011)
Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke
Jeffrey A. Switzer et al.
STROKE (2011)
EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation
Peter Seizer et al.
ATHEROSCLEROSIS (2010)
To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition
Jennifer A. Jacobsen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Changes of Matrix Metalloproteinase-9 Level Is Associated With Left Ventricular Remodeling Following Acute Myocardial Infarction Among Patients Treated With Trandolapril, Valsartan or Both
Sakiko Miyazaki et al.
CIRCULATION JOURNAL (2010)
Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production
Eric Boilard et al.
SCIENCE (2010)
Influence of elastin-derived peptides on metalloprotease production in endothelial cells
Krzysztof Siemianowicz et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2010)
Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium
Dachun Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site
Vishal Trivedi et al.
CELL (2009)
Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Daisuke Yamamoto et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins
Julien Villeneuve et al.
EXPERIMENTAL HEMATOLOGY (2009)
Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand
L. Menchen et al.
GUT (2009)
Membrane-type 1 Matrix Metalloproteinase Regulates Macrophage-dependent Elastolytic Activity and Aneurysm Formation in Vivo
Wanfen Xiong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo
Stefania Momi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
EMMPRIN (CD 147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction
Peter Seizer et al.
THROMBOSIS AND HAEMOSTASIS (2009)
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease
Joseph D. Raffetto et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Inhibitory profiles of captopril on matrix metalloproteinase-9 activity
Daisuke Yamamoto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
MMP-2 regulates human platelet activation by interacting with integrin αIIbβ3
W. -S . Choi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities
William G. Stetler-Stevenson
SCIENCE SIGNALING (2008)
Role of metalloproteinases in platelet function
Maria Jose Santos-Martinez et al.
THROMBOSIS RESEARCH (2008)
Potentiation and priming of platelet activation: a potential target for antiplatelet therapy
Paolo Gresele et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation
Philippe Van Lint et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury:: lack of inhibition by aspirin
Emanuela Falcinelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site
Daisuke Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Enhanced cardiac production of matrix metalloproteinase-2 and-9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction
Satoshi Yasuda et al.
CLINICAL SCIENCE (2007)
Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability
Jason L. Johnson et al.
CARDIOVASCULAR RESEARCH (2006)
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction - Results of the PREMIER (prevention of myocardial infarction early remodeling) trial
Michael P. Hudson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304)
G. Song et al.
PHARMACOLOGICAL RESEARCH (2006)
Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation
Ye-Ming Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure
S Ichihara et al.
CARDIOVASCULAR RESEARCH (2006)
Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells -: Implications in acute myocardial infarction
R Schmidt et al.
CIRCULATION (2006)
Intraplatelet signaling mechanisms of the priming effect of matrix metal loproteinase-2 on platelet aggregation
E Falcinelli et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction
R Nakaya et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia
ZZ Gu et al.
JOURNAL OF NEUROSCIENCE (2005)
Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial
DL Brown et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Expression of matrix metalloproteinase-9 in human platelets:: regulation of platelet activation in in vitro and in vivo studies
JR Sheu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction
J Li et al.
CLINICAL CHEMISTRY (2004)
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery
JT Peterson
HEART FAILURE REVIEWS (2004)
Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats
TM Camp et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2004)
Structure and evolutionary aspects of matrix metalloproteinases: A brief overview
S Das et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2003)
Matrix metalloproteinases and tissue inhibitors of metalloproteinases - Structure, function, and biochemistry
R Visse et al.
CIRCULATION RESEARCH (2003)
Vulnerable atherosclerotic plaque - A multifocal disease
W Casscells et al.
CIRCULATION (2003)
Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms
MW Manning et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques
B Axisa et al.
STROKE (2002)
Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function
SW Galt et al.
CIRCULATION RESEARCH (2002)
Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
LM Coussens et al.
SCIENCE (2002)
Pharmacological characteristics of solid-phase von Willebrand factor in human platelets
A Radomski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Structural analysis of the α2 integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction
TP Stricker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization
M Crisby et al.
CIRCULATION (2001)
Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms
R Pyo et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
β-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction
H Senzaki et al.
CIRCULATION RESEARCH (2000)
分享论文
